var data={"title":"Ceftriaxone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ceftriaxone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5848?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">see &quot;Ceftriaxone: Drug information&quot;</a> and <a href=\"topic.htm?path=ceftriaxone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ceftriaxone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148198\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Rocephin [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148199\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ceftriaxone for Injection;</li>\n      <li>Ceftriaxone for Injection USP;</li>\n      <li>Ceftriaxone Sodium for Injection;</li>\n      <li>Ceftriaxone Sodium for Injection BP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046122\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (Third Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442229\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Use cefotaxime in place of ceftriaxone if hyperbilirubinemia is present or if patient is receiving calcium-containing intravenous solutions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book </i>[AAP 2015]): IM, IV: 50 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infections </b>(CDC [Workowski 2015]): <b>Note: </b>Administer cautiously to hyperbilirubinemic neonates, especially those born premature; alternative agent may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis, asymptomatic neonates born to mothers with gonococcal infection: IM, IV: 25 to 50 mg/kg as a single dose; maximum dose: 125 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Disseminated infection (including sepsis, arthritis, and meningitis)/Scalp abscess: </i>IM, IV: 25 to 50 mg/kg/dose every 24 hours for 7 days, up to 10 to 14 days if meningitis is documented</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Ophthalmia neonatorum:</i> IM, IV: 25 to 50 mg/kg as a single dose; maximum dose: 125 mg/dose; <b>Note: </b>May also be used for prophylaxis if erythromycin ointment is not available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis, non-gonococcal:</b> Limited data available, dose not established: <b>Note:</b> In neonates, current IDSA guidelines suggest cefotaxime as the preferred nonpseudomonal third-generation cephalosporin; no ceftriaxone dosing is provided in the guidelines (IDSA [Tunkel 2004]). Dosing based on an open-label prospective trial of 71 patients (age range: PNA 14 days to 15 years) which included 26 patients diagnosed with meningitis and a pharmacokinetic analysis of 20 neonates and infants (n=12 neonates; including six with PNA &lt;14 days) with sepsis or meningitis; both trials reported adequate CSF penetration and favorable response (Martin 1984; Yogev 1986). IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &lt;14 days: 50 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &ge;14 days: 100 mg/kg for one dose, followed by 80 to 100 mg/kg/dose once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046115\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">see &quot;Ceftriaxone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection </b>(<i>Red Book</i> [AAP 2015])<b>:</b> Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection: 50 to 75 mg/kg/dose once daily; maximum daily dose: 1,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection: 100 mg/kg/<b>day</b> divided every 12 to 24 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chancroid:</b> Infants, Children, and Adolescents: IM: 50 mg/kg as a single dose; maximum dose: 250 mg/dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, bacterial (non-gonococcal):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis for dental and upper respiratory procedures (patients allergic to penicillins and/or unable to take oral): Infants, Children, and Adolescents: IM, IV: 50 mg/kg 30 to 60 minutes prior to procedure; maximum dose: 1,000 mg/dose (<i>Red Book</i> [AAP 2015]; Wilson 2007). <b>Note: </b>AHA guidelines (Baltimore 2015) limit the use of prophylactic antibiotics to patients at the highest risk for infective endocarditis (IE) or adverse outcomes (eg, prosthetic heart valves, patients with previous IE, unrepaired cyanotic congenital heart disease, repaired congenital heart disease with prosthetic material or device during first 6 months after procedure, repaired congenital heart disease with residual defects at the site or adjacent to site of prosthetic patch or device, and heart transplant recipients with cardiac valvulopathy).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Children and Adolescents: IV: 100 mg/kg/<b>day</b> divided every 12 hours or 80 mg/kg/dose every 24 hours; maximum daily dose: 4,000 mg/<b>day</b>, daily doses over 2,000 mg should be divided into 2 doses; treat for at least 4 weeks; longer durations may be necessary; may use in combination with other antibiotics based on organism (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Enteric infection, bacteria, empiric therapy pending diagnostic studies (HIV-exposed/-positive): </b>Adolescents: IV: 1,000 mg every 24 hours (HHS [OI adult] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gonococcal infections, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bacteremia </i>(CDC [Workowski 2015])<i>:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children weighing &le;45 kg: IM, IV: 50 mg/kg/dose once daily for 7 days; maximum dose: 1,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children weighing &gt;45 kg and Adolescents: IM, IV: 1,000 mg once daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Epididymitis, acute</i>: Adolescents: IM: 250 mg in a single dose in combination with doxycycline (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Uncomplicated cervicitis, pharyngitis, proctitis, urethritis, and vulvovaginitis (</i>CDC [Workowski 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children weighing &le;45 kg: IM, IV: 25 to 50 mg/kg as a single dose; maximum dose: 125 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children weighing &gt;45 kg and Adolescents: IM: 250 mg as a single dose in combination with single oral dose of azithromycin</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Disseminated infection (arthritis or arthritis-dermatitis syndrome)</i> (CDC [Workowski 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IM, IV: 50 mg/kg/dose once daily for 7 days; maximum dose: 1,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IM, IV: 1,000 mg once daily for 7 days; use in combination with a single oral dose of azithromycin</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conjunctivitis</i>: Adolescents: IM: 1,000 mg in a single dose in combination with a single oral dose of azithromycin (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Meningitis: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children weighing &lt;45 kg: IV, IM: 50 mg/kg/<b>day</b> divided every 12 to 24 hours for 10 to 14 days; maximum daily dose: 2,000 mg/<b>day</b>; use in combination with oral erythromycin (<i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children weighing &ge;45 kg and Adolescents: IV: 1,000 to 2,000 mg every 12 to 24 hours for 10 to 14 days; use in combination with a single dose of oral azithromycin (CDC [Workowski 2015]; <i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Endocarditis: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children weighing &lt;45 kg: IV, IM: 50 mg/kg/<b>day</b> divided every 12 to 24 hours for at least 28 days; maximum daily dose: 2,000 mg/<b>day</b>; use in combination with oral erythromycin (<i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children weighing &ge;45 kg and Adolescents: IV: 1,000 to 2,000 mg every 12 to 24 hours for at least 28 days; use in combination with a single dose of azithromycin (CDC [Workowski 2015]; <i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 50 to 75 mg/kg/<b>day</b> divided every 12 to 24 hours; maximum daily dose: 2,000 mg/<b>day</b> (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme disease, neurologic involvement, persistent/recurrent arthritis, heart block, or carditis:</b> Infants, Children, and Adolescents: IV: 50 to 75 mg/kg/dose once daily; maximum dose: 2,000 mg/dose; duration dependent on symptoms and response (AAN [Halperin 2007]; IDSA [Wormser 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b> Infants, Children, and Adolescents: IM, IV: Loading dose of 100 mg/kg may be administered at the start of therapy; maximum dose: 4,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: 100 mg/kg/<b>day</b> divided every 12 to 24 hours for 7 to 14 days; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IDSA guidelines (IDSA [Tunkel 2004]): 80 to 100 mg/kg/<b>day</b> divided every 12 to 24 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningococcal infection, chemoprophylaxis for high-risk contacts (close exposure to patients with invasive meningococcal disease)</b> (<i>Red Book </i>[AAP 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &lt;15 years: IM: 125 mg in a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;15 years: IM: 250 mg in a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute</b> (AAP [Lieberthal 2013];<i> Red Book</i> [AAP 2015]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acute bacterial: IM, IV: 50 mg/kg in a single dose; maximum dose: 1,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persistent or relapsing: IM, IV: 50 mg/kg/dose once daily for 3 days; maximum dose: 1,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis), prophylaxis for patients receiving peritoneal dialysis who require dental procedures:</b> Infants, Children, and Adolescents: IM, IV: 50 mg/kg administered 30 to 60 minutes before dental procedure; maximum dose: 1,000 mg/dose (ISPD [Warady 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia:</b> <i>Community-acquired (CAP)</i>: (IDSA/PIDS [Bradley 2011]): Infants &gt;3 months, Children, and Adolescents: IV: 50 to 100 mg/kg/<b>day</b> divided every 12 to 24 hours; maximum daily dose: 2,000 mg/<b>day</b>; higher maximum daily doses as high as 4,000 mg/<b>day</b> have been recommended for HIV-exposed/-positive patients (HHS [OI pediatric 2013]). <b>Note:</b> May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. Use the higher end of the range for penicillin-resistant <i>S. pneumoniae</i>; in children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out; preferred in patients not fully immunized for <i>H. influenzae</i> type b and S. pneumoniae, or significant local resistance to penicillin in invasive pneumococcal strains.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prophylaxis against sexually transmitted diseases following sexual assault</b> (CDC [Workowski 2015]): Adolescents: IM: 250 mg as a single dose in combination with azithromycin and metronidazole (or tinidazole)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinosinusitis, acute bacterial:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ambulatory patients: Children and Adolescents: IM, IV: 50 mg/kg as a single dose; maximum dose: 2,000 mg/dose; use for patients who are unable to tolerate oral medication, or unlikely to be adherent to the initial doses of antibiotic (AAP [Wald 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection requiring hospitalization: Infants, Children, and Adolescents: IV: 50 mg/kg/<b>day</b> divided every 12 hours for 10 to 14 days; maximum daily dose: 2,000 mg/<b>day</b> (IDSA [Chow 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Salmonellosis:</b> <b>Note:</b> Salmonella in healthy patients typically does not require antibiotic treatment as it generally resolves in 5 to 7 days (CDC 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;6 months of age or Infants, Children, and Adolescents who have severe infection, prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia: Non-<i>typhi</i> species diarrhea: IM, IV: 100 mg/kg/<b>day</b> divided every 12 to 24 hours for 14 days; or longer if relapsing. <b>Note:</b> Not recommended for routine use (Guerrant 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-positive: Adolescents: IV: 1,000 mg every 24 hours; duration dependent upon CD4 counts and presence of bacteremia (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If CD4 count &ge;200 cells/mm<sup>3</sup>: 7 to 14 days; if bacteremia present: At least 14 days; longer durations if bacteremia or if infection is complicated</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If CD4 count &lt;200 cells/mm<sup>3</sup>: 2 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Shigellosis:</b> Infants, Children, and Adolescents: IM, IV: 50 to 100 mg/kg/dose once daily; maximum daily dose: 4,000 mg/<b>day</b>; usual duration 5 days; may shorten duration to 2 days if clinical response good and no extraintestinal involvement (<i>Red Book</i> [AAP 2015]; WHO 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin/skin structure infections:</b> Infants, Children, and Adolescents: IM, IV: 50 to 75 mg/kg/<b>day</b> in 1 to 2 divided doses; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>S. pneumoniae</b></i>\n      <b> infection, invasive</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CNS infection: 100 mg/kg/<b>day</b> divided every 12 hours; maximum daily dose: 4,000 mg/<b>day </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-CNS infection: 50 to 75 mg/kg/<b>day</b> divided every 12 to 24 hours; maximum daily dose: 1,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> Children and Adolescents: IV: 50 to 75 mg/kg within 60 minutes prior to the procedure; maximum dose: 2,000 mg/dose (ASHP/IDSA [Bratzler 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Syphilis: Note:</b> Not considered first-line therapy and use should be reserved for special circumstances with close monitoring and follow-up:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Congenital syphilis, treatment (CDC [Workowski 2015]): <b>Note:</b> There is insufficient data regarding the use of ceftriaxone for treatment of congenital syphilis (penicillin is recommended); use should be reserved for situations of penicillin shortage.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;30 days: IM, IV: 75 mg/kg/dose once daily for 10 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: IM, IV: 100 mg/kg/dose once daily for 10 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Postexposure prophylaxis (HIV-exposed/-positive): Adolescents: IM, IV: 1,000 mg once daily for 8 to 10 days (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Early syphilis (independent of HIV status): Adolescents: IM, IV: 1,000 to 2,000 mg once daily for 10 to 14 days; optimal dose and duration have not been defined (CDC [Workowski 2015]; HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Neurosyphillis, otic, ocular disease (HIV-exposed/-positive; penicillin-allergic): Adolescents: IM, IV: 2,000 mg once daily for 10 to 14 days (CDC [Workowski 2015). <b>Note:</b> Penicillin desensitization is the preferred approach; use should be reserved when desensitization is not feasible (HHS [OI adult 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Typhoid fever:</b> Infants, Children, and Adolescents: IV: 80 mg/kg/dose once daily for 14 days (Stephens 2002). <b>Note: </b>Ceftriaxone is reserved for patients who have failed oral therapy or who have severe disease, intestinal complications, or obtundation and cannot take oral medications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infections:</b> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children 2 to 24 months: 50 to 75 mg/kg/dose once daily (AAP 2011; Bradley 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;24 months and Adolescents: 50 mg/kg/dose once daily; maximum dose: 2,000 mg/dose (Bradley 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosage, susceptible infection:</b> IM, IV: 1,000 to 2,000 mg every 12 to 24 hours, depending on the type and severity of infection; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chancroid:</b> IM: 250 mg as single dose (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cholecystitis, mild to moderate:</b> IM, IV: 1,000 to 2,000 mg every 12 to 24 hours for 4 to 7 days (provided source controlled) (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gonococcal infections</b> (CDC [Workowski 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conjunctivitis, complicated: IM: 1,000 mg in a single dose plus oral azithromycin; additionally, consider a one-time saline lavage of the infected eye. Data on treatment in adults are limited, consultation with an infectious disease specialist should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Disseminated gonococcal infection (arthritis and arthritis-dermatitis syndrome): IM, IV: 1,000 mg once daily plus single dose oral azithromycin; continue for 24 to 48 hours after clinical improvement, then may switch to an oral agent guided by antimicrobial susceptibility to complete a total of at least 7 days of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocarditis: IV: 1,000 to 2,000 mg every 12 to 24 hours plus oral azithromycin; continue ceftriaxone for at least 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Epididymitis, acute: IM: 250 mg in a single dose in combination with oral antibiotics (doxycycline, levofloxacin, or ofloxacin) (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningitis: IV: 1,000 to 2,000 mg every 12 to 24 hours plus oral azithromycin; continue ceftriaxone for 10 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Uncomplicated cervicitis, pharyngitis, proctitis, urethritis: IM: 250 mg in a single dose plus oral azithromycin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Infective endocarditis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment (AHA [Baddour 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Enterococcus:</i> IV: 2,000 mg every 12 hours for 6 weeks with concomitant ampicillin</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>HACEK organisms,</i> <i>Viridans group Streptococcus (VGS), and S. bovis: </i>IV, IM: 2,000 mg once daily; duration and use of concomitant gentamicin is dependent on organism, susceptibility, and valve type</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis: IM, IV: 1,000 mg 30 to 60 minutes before procedure (AHA [Wilson 2007]). Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated, community-acquired, mild to moderate (in combination with metronidazole):</b> IV: 1,000 to 2,000 mg every 12 to 24 hours for 4 to 7 days (provided source controlled) (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme neuroborreliosis:</b> IV: 2,000 mg once daily for 14 days (AAN [Halperin 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis (empiric treatment):</b> IV: 2,000 mg every 12 hours for 7 to 14 days (longer courses may be necessary for selected organisms)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningococcal infection, chemoprophylaxis for high-risk contacts (close exposure to patients with invasive meningococcal disease):</b> IM: 250 mg in a single dose (CDC 2005; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic inflammatory disease (mild to moderately severe): </b>IM: 250 mg in a single dose plus oral doxycycline (with or without oral metronidazole) (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Proctitis, proctocolitis, enteritis:</b> IM: 250 mg in a single dose plus oral doxycycline (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prophylaxis against sexually transmitted diseases following sexual assault:</b> IM: 250 mg as a single dose in combination with azithromycin and metronidazole (or tinidazole) (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pyelonephritis (acute, uncomplicated):</b> IV: 1,000 to 2,000 mg once daily; after improvement, may be switched to an oral regimen to complete a 1- to 2-week treatment course (Grabe 2015). In females, some clinicians administer a single dose of 1,000 mg before initiating oral outpatient empiric therapy (IDSA [Gupta 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinosinusitis, acute bacterial, severe infection requiring hospitalization:</b> IV: 1,000 to 2,000 mg every 12 to 24 hours for 5 to 7 days (IDSA [Chow 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> IV: 1,000 mg 30 minutes to 2 hours before surgery</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cholecystectomy: 1,000 to 2,000 mg every 12 to 24 hours, discontinue within 24 hours unless infection outside gallbladder suspected (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Syphilis (primary or secondary):</b> IM, IV: 1,000 to 2,000 mg once daily for 10 to 14 days; <b>Note:</b> Alternative treatment for early syphilis, optimal dose, and duration have not been defined (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment is generally necessary in renal impairment; <b>Note:</b> Concurrent renal and hepatic dysfunction: Adult maximum daily dose: &le;2,000 mg/<b>day.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD) (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No adjustment is generally necessary in hepatic impairment; <b>Note:</b> Concurrent renal and hepatic dysfunction: Adult maximum daily dose: &le;2,000 mg/<b>day</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148175\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/mL (50 mL); 40 mg/mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rocephin: 500 mg (1 ea [DSC]); 1 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg (1 ea); 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea); 100 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg (1 ea); 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148159\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046125\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Do not coadminister with calcium-containing solutions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Administer IM injections deep into a large muscle mass  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intermittent IV infusion: Administer over 30 minutes; shorter infusion times (15 minutes) have been reported (Yogev 1986) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IVP: Administration over 2 to 4 minutes has been reported in pediatric patients &gt;11 years and adults primarily in the outpatient setting (Baumgartner 1983; Garrelts 1988; Poole 1999) and over 5 minutes in pediatric patients ages newborn to 15 years with meningitis (Grubbauer 1990; Martin 1984). Rapid IVP injection over 5 minutes of a 2,000 mg dose resulted in tachycardia, restlessness, diaphoresis, and palpitations in an adult patient (Lossos 1994). IV push administration in young infants may also have been a contributing factor in risk of cardiopulmonary events occurring from interactions between ceftriaxone and calcium (Bradley 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148192\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder for injection: Prior to reconstitution, store at &le;25&deg;C (&le;77&deg;F). Protect from light. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Premixed solution (manufacturer premixed): Store at -20&deg;C; once thawed, solutions are stable for 3 days at 25&deg;C (77&deg;F) or for 21 days at 5&deg;C (41&deg;F). Do not refreeze. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Stability of reconstituted solutions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 to 40 mg/mL: Reconstituted in D<sub>5</sub>W, D<sub>10</sub>W, NS, or SWFI: Stable for 2 days at room temperature of 25&deg;C (77&deg;F) or for 10 days when refrigerated at 4&deg;C (39&deg;F). Stable for 26 weeks when frozen at  -20&deg;C when reconstituted with D<sub>5</sub>W or NS. Once thawed (at room temperature), solutions are stable for 2 days at room temperature of 25&deg;C (77&deg;F) or for 10 days when refrigerated at 4&deg;C (39&deg;F); does not apply to manufacturer's premixed bags. Do not refreeze. If D<sub>5</sub>NS or D<sub>5</sub><sup>1</sup>/<sub>2</sub>NS are used, solutions are only stable for 2 days at of 25&deg;C (77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Reconstituted in D<sub>5</sub>W, SWFI, or NS: Stable for 2 days at room temperature of 25&deg;C (77&deg;F) or for 10 days when refrigerated at 4&deg;C (39&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Reconstituted in lidocaine 1% solution or bacteriostatic water: Stable for 24 hours at room temperature of 25&deg;C (77&deg;F) or for 10 days when refrigerated at 4&deg;C (39&deg;F). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 to 350 mg/mL: Reconstituted in D<sub>5</sub>W, NS, lidocaine 1% solution, bacteriostatic water, or SWFI: Stable for 24 hours at room temperature of 25&deg;C (77&deg;F) or for 3 days when refrigerated at 4&deg;C (39&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046124\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of sepsis, meningitis, infections of the lower respiratory tract, acute bacterial otitis media, skin and skin structure, bone and joint, intra-abdominal and urinary tract due to susceptible organisms (FDA approved in infants, children, adolescents, and adults); surgical prophylaxis (FDA approved in adults); documented or suspected uncomplicated gonococcal infection or pelvic inflammatory disease (FDA approved for adults); has also been used for the treatment of endocarditis, Lyme disease, acute bacterial rhinosinusitis, salmonellosis, shigellosis, syphilis, and typhoid fever and prophylaxis of peritonitis in patients undergoing invasive dental procedures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148257\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CefTRIAXone may be confused with ceFAZolin, cefoTEtan, cefOXitin, cefTAZidime, Cetraxal</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rocephin may be confused with Roferon</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148254\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash, skin tightness (IM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Eosinophilia, leukopenia, thrombocythemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Induration at injection site (incidence higher with IM), pain at injection site, tenderness at injection site, warm sensation at injection site (IM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal pain, acute generalized exanthematous pustulosis, acute renal failure (post-renal), agranulocytosis, allergic dermatitis, anaphylactoid reaction, anaphylaxis, anemia, basophilia, blood coagulation disorder, bronchospasm, candidiasis, casts in urine, choledocholithiasis, cholelithiasis, clostridium difficile associated diarrhea, colitis, decreased prothrombin time, dysgeusia, dyspepsia, edema, epistaxis, erythema multiforme, fever, flushing, gallbladder sludge, glossitis, glycosuria, granulocytopenia, headache, hematuria, hemolytic anemia, hypersensitivity pneumonitis, increased monocytes, increased serum alkaline phosphatase, increased serum bilirubin, increased serum creatinine, jaundice, kernicterus, leukocytosis, lymphocytopenia, lymphocytosis, nephrolithiasis, neutropenia, oliguria, palpitations, pancreatitis, phlebitis, prolonged prothrombin time, pseudomembranous colitis, seizure, serum sickness, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, toxic epidermal necrolysis, ureteral obstruction, urogenital fungal infection, urolithiasis, vaginitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148182\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ceftriaxone, any component of the formulation, or other cephalosporins; <b>do not use in hyperbilirubinemic neonates</b>, particularly those who are premature since ceftriaxone is reported to displace bilirubin from albumin binding sites; concomitant use with intravenous calcium-containing solutions/products in neonates (&le;28 days); IV use of ceftriaxone solutions containing lidocaine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148163\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Serious and sometimes fatal hypersensitivity has been reported. Use caution in patients with a history of any allergy (particularly drugs), penicillin allergy or beta-lactam sensitivity. If severe hypersensitivity occurs, discontinue immediately and institute supportive emergency measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elevated INR: May be associated with increased INR (rarely), especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease. Monitor INR during treatment if patient has impaired synthesis or low stores of vitamin K; supplementation may be needed if clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemolytic anemia: Severe cases (including some fatalities) of immune-related hemolytic anemia have been reported in patients receiving cephalosporins, including ceftriaxone.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: Secondary to biliary obstruction, pancreatitis has been reported rarely. Most patients had biliary stasis or sludge risk factors (eg, preceding major surgery, sever illness, TPN).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gallbladder pseudolithiasis: Abnormal gallbladder sonograms have been reported, possibly due to ceftriaxone-calcium precipitates; probability is greatest in pediatric patients. Discontinue in patients who develop signs and symptoms and/or sonographic evidence of gallbladder disease. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal disease: Use with caution in patients with a history of GI disease, especially colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal/hepatic impairment (concurrent) Use with caution in patients with concurrent hepatic dysfunction and significant renal disease; dosage should not exceed 2 g/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neonates: Use extreme caution in neonates due to risk of hyperbilirubinemia, particularly in premature infants (contraindicated in hyperbilirubinemic neonates and neonates &lt;41 weeks postmenstrual age). Fatal precipitation reactions in neonates due to coadministration of calcium-containing solutions have been reported; concurrent use in neonates is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Precipitation: Ceftriaxone may complex with calcium causing precipitation. Fatal lung and kidney damage associated with calcium-ceftriaxone precipitates has been observed in premature and term neonates. Due to reports of precipitation reaction in neonates, do not reconstitute, admix, or coadminister with calcium-containing solutions (eg, LR, Hartmann&rsquo;s solution, parenteral nutrition), even via separate infusion lines/sites or at different times in any neonate. Ceftriaxone should not be diluted or administered simultaneously with any calcium-containing solution via a Y-site in any patient. However, ceftriaxone and calcium-containing solutions may be administered sequentially of one another for use in patients <b>other than neonates</b> if infusion lines are thoroughly flushed (with a compatible fluid) between infusions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298998\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148168\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13136&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts (Intravenous): May enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate. Management: Use of ceftriaxone with calcium-containing solutions within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ringer's Injection (Lactated): May enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium in the Lactated Ringer's forming an insoluble precipitate. Management: Use of ceftriaxone with calcium-containing solutions (including LR) within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148171\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5952824\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Ceftriaxone crosses the placenta. Pregnancy was found to influence the single dose pharmacokinetics of ceftriaxone when administered prior to delivery (Popovi&#263; 2007). The pharmacokinetics of ceftriaxone following multiple doses in the third trimester are similar to those of nonpregnant patients (Bourget Fernandez 1993). Ceftriaxone is recommended for use in pregnant women for the treatment of gonococcal infections, Lyme disease, and may be used in certain situations prior to vaginal delivery in women at high risk for endocarditis (consult current guidelines) (ACOG 120, 2011; CDC [Workowski 2015]; Wormser 2006). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046121\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, platelet count, PT, renal and hepatic function tests periodically; number and type of stools/day for diarrhea; observe for signs and symptoms of anaphylaxis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148162\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148181\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely throughout the body including gallbladder, lungs, bone, bile, CSF (higher concentrations achieved when meninges are inflamed); V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: 0.34 to 0.55 L/kg (Richards 1984) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children: 0.3 to 0.4 L/kg (Richards 1984) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~6 to 14 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 85% to 95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates (Martin 1984): 1 to 4 days: 16 hours; 9 to 30 days: 9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children (age not specified): 4.1 to 6.6 hours (Richards 1984) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Normal renal and hepatic function: ~5 to 9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Renal impairment (mild-to-severe): ~12 to 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 2 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (33% to 67% as unchanged drug); feces (as inactive drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21122185\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Rocephin contains 3.6 mEq sodium per gram of ceftriaxone.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323052\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CefTRIAXone Sodium in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (50 mL): $18.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (50 mL): $40.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefTRIAXone Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $2.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $9.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 g (1): $240.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $15.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $2.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefTRIAXone Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $46.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $8.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $33.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefTRIAXone Sodium-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g 3.74% (1): $13.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g 2.22% (1): $22.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148186\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acantex (AR, CL);</li>\n      <li>Aciphin (BD);</li>\n      <li>Acrocef (EC);</li>\n      <li>Actaxon (ID);</li>\n      <li>Alcizon (ET);</li>\n      <li>Amcef (MX);</li>\n      <li>Aumax (VN);</li>\n      <li>Aurofox (MX);</li>\n      <li>Aurokson (UA);</li>\n      <li>Axone (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Axtar (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Benaxona (MX);</li>\n      <li>Biotriax (ID);</li>\n      <li>Broadced (ID);</li>\n      <li>Brospec (ID);</li>\n      <li>Cafalogen (PE);</li>\n      <li>Carotan (PE);</li>\n      <li>Cef-S (PH);</li>\n      <li>Cef-Zone (TH);</li>\n      <li>Cefacrol (PE);</li>\n      <li>Cefaxona (MX);</li>\n      <li>Cefaxone (MY, SG);</li>\n      <li>Cefin (SG);</li>\n      <li>Cefizon (LK);</li>\n      <li>Cefkizon (KR);</li>\n      <li>Cefort (RO);</li>\n      <li>Cefraden (MX);</li>\n      <li>Cefriex (ID);</li>\n      <li>Ceftash (ET);</li>\n      <li>Ceftral (LK);</li>\n      <li>Ceftrex (MX, TH);</li>\n      <li>Ceftrian (EC);</li>\n      <li>Ceftrianol (MX);</li>\n      <li>Ceftriax-1 (PH);</li>\n      <li>Ceftrifil (PH);</li>\n      <li>Ceftrilem (MX);</li>\n      <li>Ceftritina (VN);</li>\n      <li>Ceftron (LK);</li>\n      <li>Cefxon (ID);</li>\n      <li>Celltriaxon (MY);</li>\n      <li>Ceptaxone (KR);</li>\n      <li>Cerixon (KR);</li>\n      <li>Cetriaf (DO);</li>\n      <li>Chef (TW);</li>\n      <li>Cikedrix (PH);</li>\n      <li>Ecotrixon (ID);</li>\n      <li>Elpicef (ID);</li>\n      <li>Eroxet (PH);</li>\n      <li>Erphacef (ID);</li>\n      <li>Excephin (ET);</li>\n      <li>Exempla (AR);</li>\n      <li>Ferfacef (ID);</li>\n      <li>Forgram (PH);</li>\n      <li>Gomcephin (KR);</li>\n      <li>Infecef (BD);</li>\n      <li>Ivixone (TZ);</li>\n      <li>Keftriaxone (IL);</li>\n      <li>Keptrix (PH);</li>\n      <li>Lendacin (HR, HU);</li>\n      <li>Longacef (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Lyceft (IN);</li>\n      <li>Megion (AE, BH, CR, GT, HN, JO, KW, LB, MX, NI, PA, PH, QA, SA, SV);</li>\n      <li>Mesporin (AE, BF, BH, BJ, CI, CY, EE, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Mesporin IM (BB, BM, BS, BZ, GY, HK, JM, PR, SR);</li>\n      <li>Mesporin IV (BB, BM, BS, BZ, GY, HK, JM, PR, SR);</li>\n      <li>Monocef (IN);</li>\n      <li>Newcef (KR);</li>\n      <li>Novosef (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PH, RU, SA, SY, TR, YE);</li>\n      <li>Oframax (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SG, SL, SN, TN, TZ, UG, VN, ZA, ZM, ZW);</li>\n      <li>Oncef (PH);</li>\n      <li>Pantrixon (PH);</li>\n      <li>Powergef (TZ);</li>\n      <li>Protsef (UA);</li>\n      <li>Retrokor (PH);</li>\n      <li>Rocefin (BR, CO, IT);</li>\n      <li>Rocefort (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Rocephalin (DK, FI, IS, NO, SE);</li>\n      <li>Rocephin &quot;Roche&quot; (CZ);</li>\n      <li>Rocephin (AE, AT, BH, CH, CN, CU, CY, DE, EC, EG, GB, GH, GR, HK, HR, HU, IE, IL, IQ, IR, JO, JP, KE, KR, KW, LB, LV, LY, MT, MX, NL, OM, PE, PH, PK, PL, PT, PY, QA, RO, SA, SG, SY, TH, TW, TZ, UG, UY, VE, VN, YE, ZM);</li>\n      <li>Rocephin Roche (CZ);</li>\n      <li>Rocephine (BE, FR, LU);</li>\n      <li>Rocidar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Rotsefin (UA);</li>\n      <li>Roxcef (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Samixon (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Sintrex (TW);</li>\n      <li>Socef (ID);</li>\n      <li>Tacex (MX);</li>\n      <li>Terbac (MX);</li>\n      <li>Tercef (BG);</li>\n      <li>Tracef (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Traxef (BD);</li>\n      <li>Traxol (ZW);</li>\n      <li>Trexofin (SG);</li>\n      <li>Triaken (MX);</li>\n      <li>Triax (IL);</li>\n      <li>Triax-1 (PH);</li>\n      <li>Triaxone (AE, ET, KR, KW, LB, QA, SA, SG);</li>\n      <li>Tricef (TW);</li>\n      <li>Tricefin (SG);</li>\n      <li>Trijec (ID);</li>\n      <li>Triox (MX);</li>\n      <li>Trixone (MY);</li>\n      <li>Trizon (BD);</li>\n      <li>Tsefast (UA);</li>\n      <li>U-Ron (TW);</li>\n      <li>Unocef (MY);</li>\n      <li>Utrixone (ZW);</li>\n      <li>Vaxcel (LK);</li>\n      <li>Veracol (NZ);</li>\n      <li>Viatrex (PH);</li>\n      <li>Xone (ZW);</li>\n      <li>Xtenda (PH);</li>\n      <li>Zefone 250 (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Zeftrox (LK);</li>\n      <li>Zontrixone (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, &quot;Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months,&quot; <i>Pediatrics</i>, 2011, 128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol</i>. 2011 Jun;117(6):1472-83. doi: 10.1097/AOG.0b013e3182238c31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/21606770/pubmed\" target=\"_blank\" id=\"21606770\">21606770</a>]</span><span class=\"doi\">10.1097/AOG.0b013e3182238c31</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bourget P, Fernandez H, Quinquis V, Delouis C. Pharmacokinetics and protein binding of ceftriaxone during pregnancy. <i>Antimicrob Agents Chemother.</i> 1993;37(1):54-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/8431018/pubmed\" target=\"_blank\" id=\"8431018\">8431018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Compogiannis LS, Murray WE, et al, &ldquo;Pharmacokinetics and Safety of Intramuscular Injection of Concentrated Ceftriaxone in Children,&rdquo; <i>Clin Pharm</i>, 1992, 11(11):961-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/1464221/pubmed\" target=\"_blank\" id=\"1464221\">1464221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Wassel RT, Lee L, et al, &quot;Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events,&quot; <i>Pediatrics</i>, 2009, 123(4):e609-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/19289450/pubmed\" target=\"_blank\" id=\"19289450\">19289450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ceftriaxone injection [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15917737\"></a>Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2005;54(RR-7):1-17. Available at <a href=\"http://www.cdc.gov/mmwr/PDF/rr/rr5407.pdf\" target=\"_blank\">http://www.cdc.gov/mmwr/PDF/rr/rr5407.pdf</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/15917737/pubmed\" target=\"_blank\" id=\"15917737\">15917737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Salmonella: Information for Healthcare Professionals and Laboratories. March 9, 2015. Available at <a href=\"https://www.cdc.gov/salmonella/general/technical.html\" target=\"_blank\">https://www.cdc.gov/salmonella/general/technical.html</a>. Accessed December 12, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frenck RW Jr, Nakhla I, Sultan Y, et al, &quot;Azithromycin Versus Ceftriaxone for the Treatment of Uncomplicated Typhoid Fever in Children,&quot; <i>Clin Infect Dis</i>, 2000, 31(5):1134-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/11073741/pubmed\" target=\"_blank\" id=\"11073741\">11073741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garrelts JC, Ast D, LaRocca J, et al, &quot;Postinfusion Phlebitis After Intravenous Push Versus Intravenous Piggyback Administration of Antimicrobial Agents,&quot; <i>Clin Pharm</i>, 1988, 7(10):760-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/3233896/pubmed\" target=\"_blank\" id=\"3233896\">3233896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grabe M, Bartoletti R, Bjerklund Johansen TE, et al. Guidelines on Urological Infections. 2015. Available at https://uroweb.org/wp-content/uploads/19-Urological-infections_LR2.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grubbauer HM, Dornbusch HJ, Dittrich P, et al, &quot;Ceftriaxone Monotherapy for Bacterial Meningitis in Children,&quot; <i>Chemotherapy</i>, 1990, 36(6):441-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/2292206/pubmed\" target=\"_blank\" id=\"2292206\">2292206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guerrant RL, Van Gilder T, Steiner TS, et al, &quot;Practice Guidelines for the Management of Infectious Diarrhea,&quot; <i>Clin Infect Dis</i>, 2001, 32(3):331-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/11170940/pubmed\" target=\"_blank\" id=\"11170940\">11170940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21292654\"></a>Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/21292654/pubmed\" target=\"_blank\" id=\"21292654\">21292654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halperin JJ, Shapiro ED, Logigian E, et al, &quot;Practice Parameter: Treatment of Nervous System Lyme Disease (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology,&quot; <i>Neurology</i>, 2007, 69(1):91-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/17522387/pubmed\" target=\"_blank\" id=\"17522387\">17522387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. December 2015. Available at: <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed March 17, 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kafetzis DA, Brater DC, Fanourgakis JE, Voyatzis J, Georgakopoulos P. Ceftriaxone distribution between maternal blood and fetal blood and tissues at parturition and between blood and milk postpartum. <i>Antimicrob Agents Chemother</i>. 1983;23(6):870-873.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6311089/pubmed\" target=\"_blank\" id=\"6311089\">6311089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al, &quot;The Diagnosis and Management of Acute Otitis Media,&quot; <i>Pediatrics</i>, 2013, 131(3):e964-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lossos IS and Lossos A, &quot;Hazards of Rapid Administration of Ceftriaxone,&quot; <i>Ann Pharmacother</i>, 1994, 28(6):807-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/7919578/pubmed\" target=\"_blank\" id=\"7919578\">7919578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin E, Koup JR, Paravicini U, et al, &quot;Pharmacokinetics of Ceftriaxone in Neonates and Infants With Meningitis,&quot; <i>J Pediatr</i>, 1984, 105(3):475-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6088747/pubmed\" target=\"_blank\" id=\"6088747\">6088747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poole SM, Nowobilski-Vasilios A, and Free F, &quot;Intravenous Push Medications in the Home,&quot; <i>J Intraven Nurs</i>, 1999, 22(4):209-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/10476138/pubmed\" target=\"_blank\" id=\"10476138\">10476138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Popovi&#263; J, Gruji&#263; Z, Sabo A. Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women. <i>J Clin Pharm Ther</i>. 2007;32(6):595-602.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/18021337/pubmed\" target=\"_blank\" id=\"18021337\">18021337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richards DM, Heel RC, Brogden RN, et al, &ldquo;Ceftriaxone: A Review of Its Antibacterial Activity, Pharmacological Properties and Therapeutic Use,&rdquo; <i>Drugs</i>, 1984, 27(6):469-527.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6329638/pubmed\" target=\"_blank\" id=\"6329638\">6329638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 15;50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stephens I and Levine MM, &quot;Management of Typhoid Fever in Children,&quot;<i> Pediatr Infect Dis J</i>, 2002, 21(2):157-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/11840084/pubmed\" target=\"_blank\" id=\"11840084\">11840084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wald ER, Applegate KE, Bordley C, et.al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1-18 years. <i>Pediatrics</i>. 2013;132:e262-280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/23796742/pubmed\" target=\"_blank\" id=\"23796742\">23796742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, 32(Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; <i>Circulation</i>, 2007, 115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &quot;Guidelines for the Control of Shigellosis, Including Epidemics Due to Shigella dysenteriae Type 1,&quot; 2005. Available at http://whqlibdoc.who.int/publications/2005/9241592330.pdf </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al, &quot;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yogev R, Shulman ST, Chadwick EG, et al, &quot;Once Daily Ceftriaxone for Central Nervous System Infections and Other Serious Pediatric Infections,&quot; <i>Pediatr Infect Dis</i>, 1986, 5(3):298-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/3725639/pubmed\" target=\"_blank\" id=\"3725639\">3725639</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13136 Version 195.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F148198\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F148199\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046122\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442229\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046115\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F148175\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F148159\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046125\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F148192\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046124\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F148257\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F148254\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F148182\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F148163\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298998\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F148168\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F148171\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5952824\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046121\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F148162\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F148181\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F21122185\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323052\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F148186\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13136|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">Ceftriaxone: Drug information</a></li><li><a href=\"topic.htm?path=ceftriaxone-patient-drug-information\" class=\"drug drug_patient\">Ceftriaxone: Patient drug information</a></li></ul></div></div>","javascript":null}